Key Highlights

  • Shares trading down 4.63% to $4.12 in today's session.
  • Trading Volume reached 397.37 thousand shares.
  • The company reported an EPS of negative $0.47.
  • The company must still meet a separate Equity requirement by January 2027.

Nasdaq Confirms Bid Price Compliance Following Reverse Split

Nexalin Technology, Inc. (NASDAQ:NXL), a Texas-based medical device company developing non-invasive brain stimulation therapies for mental health conditions, said it received written confirmation from Nasdaq that it regained compliance with the exchange's minimum bid price rule, after its stock closed above $1.00 for 21 consecutive trading days following an earlier reverse stock split.

Equity Requirement Still Outstanding

The confirmation follows a Nasdaq Hearings Panel decision granting the company's request for continued listing. The company still needs to demonstrate compliance with a separate minimum stockholders' equity requirement by January 2027 to maintain its listing, leaving some uncertainty around its long-term exchange status.

Shares Fall Despite Positive Listing News

Despite resolving one of its two compliance issues, shares fell today, with an EPS of negative $0.47 reflecting the company's current financial position. The company highlighted other recent developments, including a new distribution agreement covering several South American markets, as part of its push toward commercial Revenue generation.

Outlook: Equity Compliance Deadline Looms in Early 2027

With the bid price issue resolved, investor attention may now shift to whether the company can meet the stockholders' equity requirement ahead of its January 2027 deadline. The company's ongoing clinical trial in insomnia remains a separate catalyst as it pursues broader FDA Marketing authorization.